BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xia H, Chen J, Shi M, Deivasigamani A, Ooi LL, Hui KM. The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma. Oncotarget 2015;6:5990-6000. [PMID: 25714025 DOI: 10.18632/oncotarget.3337] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Sales L, de Sousa GR, Ferreira-Silva GÁ, Castro-Gamero AM, Ionta M, de Oliveira JC. YM155 induces apoptosis in p53-deficient T-acute lymphoblastic leukemia cells independent of survivin inhibition. Anticancer Drugs 2017;28:298-306. [PMID: 27930382 DOI: 10.1097/CAD.0000000000000462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
2 Liu C, Wen C, Wang X, Wei Y, Xu C, Mu X, Zhang L, Wang X, Tian J, Ma P, Meng F, Zhang Q, Zhao N, Yu B, Gong T, Guo R, Wang H, Xie J, Sun G, Li G, Zhang H, Qin Q, Xu J, Dong X, Wang L. Golgi membrane protein GP73 modified-liposome mediates the antitumor effect of survivin promoter-driven HSVtk in hepatocellular carcinoma. Exp Cell Res 2019;383:111496. [PMID: 31306654 DOI: 10.1016/j.yexcr.2019.111496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Zhang B, Wang N, Zhang C, Gao C, Zhang W, Chen K, Wu W, Chen Y, Tan C, Liu F, Jiang Y. Novel multi-substituted benzyl acridone derivatives as survivin inhibitors for hepatocellular carcinoma treatment. Eur J Med Chem 2017;129:337-48. [PMID: 28237663 DOI: 10.1016/j.ejmech.2017.02.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
4 Li Y, Guo M, Lin Z, Zhao M, Xiao M, Wang C, Xu T, Chen T, Zhu B. Polyethylenimine-functionalized silver nanoparticle-based co-delivery of paclitaxel to induce HepG2 cell apoptosis. Int J Nanomedicine 2016;11:6693-702. [PMID: 27994465 DOI: 10.2147/IJN.S122666] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 8.8] [Reference Citation Analysis]
5 Noorwali A, Faidah M, Ahmed N, Bima A. Tracking iron oxide labelled mesenchymal stem cells(MSCs) using magnetic resonance imaging (MRI) in a rat model of hepatic cirrhosis. Bioinformation 2019;15:1-10. [PMID: 31359992 DOI: 10.6026/97320630015001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Yu J, Wang Z, Zhang H, Wang Y, Li DQ. Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma. World J Gastroenterol 2021; 27(43): 7546-7562 [PMID: 34887648 DOI: 10.3748/wjg.v27.i43.7546] [Reference Citation Analysis]
7 Cheng XJ, Lin JC, Ding YF, Zhu L, Ye J, Tu SP. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues. Oncotarget 2016;7:7096-109. [PMID: 26771139 DOI: 10.18632/oncotarget.6898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
8 Dong H, Wang M, Chang C, Sun M, Yang F, Li L, Feng M, Zhang L, Li Q, Zhu Y, Qiao Y, Xie T, Chen J. Erianin inhibits the oncogenic properties of hepatocellular carcinoma via inducing DNA damage and aberrant mitosis. Biochem Pharmacol 2020;182:114266. [PMID: 33035506 DOI: 10.1016/j.bcp.2020.114266] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Qiao Y, Pei Y, Luo M, Rajasekaran M, Hui KM, Chen J. Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma. Exp Biol Med (Maywood) 2021;246:1343-54. [PMID: 33899543 DOI: 10.1177/15353702211008380] [Reference Citation Analysis]
10 Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform 2021;22:bbaa164. [PMID: 32789496 DOI: 10.1093/bib/bbaa164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Yang C, Chen J, Li Y, Huang X, Liu Z, Wang J, Jiang H, Qin W, Lv Y, Wang H, Wang C. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Brief Bioinform 2021;22:bbaa295. [PMID: 33167027 DOI: 10.1093/bib/bbaa295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Su C. Survivin in survival of hepatocellular carcinoma. Cancer Lett. 2016;379:184-190. [PMID: 26118774 DOI: 10.1016/j.canlet.2015.06.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
13 Michaelis M, Wass MN, Reddin I, Voges Y, Rothweiler F, Hehlgans S, Cinatl J, Mernberger M, Nist A, Stiewe T, Rödel F, Cinatl J Jr. YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting. Cancers (Basel) 2020;12:E1080. [PMID: 32357518 DOI: 10.3390/cancers12051080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Shojaei Moghadam K, Farshdousti Hagh M, Alivand MR, Fardi M, Movassaghpour AA, Mohammadi A, Moghadasi M, Solali S. Emerging Effects of Sepantronium Bromide (YM155) on MOLT-4 Cell Line Apoptosis Induction and Expression of Critical Genes Involved in Apoptotic Pathways. Adv Pharm Bull 2020;10:81-7. [PMID: 32002365 DOI: 10.15171/apb.2020.010] [Reference Citation Analysis]
15 Scarabel L, Perrone F, Garziera M, Farra R, Grassi M, Musiani F, Russo Spena C, Salis B, De Stefano L, Toffoli G, Rizzolio F, Tonon F, Abrami M, Chiarappa G, Pozzato G, Forte G, Grassi G, Dapas B. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. Expert Opinion on Drug Delivery 2017;14:797-810. [DOI: 10.1080/17425247.2017.1292247] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
16 Farra R, Musiani F, Perrone F, Čemažar M, Kamenšek U, Tonon F, Abrami M, Ručigaj A, Grassi M, Pozzato G, Bonazza D, Zanconati F, Forte G, El Boustani M, Scarabel L, Garziera M, Russo Spena C, De Stefano L, Salis B, Toffoli G, Rizzolio F, Grassi G, Dapas B. Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness. Molecules 2018;23:E777. [PMID: 29597300 DOI: 10.3390/molecules23040777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Reghupaty SC, Sarkar D. Current Status of Gene Therapy in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1265. [PMID: 31466358 DOI: 10.3390/cancers11091265] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
18 Mazzio EA, Lewis CA, Elhag R, Soliman KF. Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response. Cancer Genomics Proteomics 2018;15:249-64. [PMID: 29976630 DOI: 10.21873/cgp.20083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]